Novak Alfred J 4

4 · Pasithea Therapeutics Corp. · Filed May 5, 2026

AI-generated summary of this filing

Updated May 5, 2026

Pasithea (KTTA) Director Alfred J. Novak Receives Stock Award

What Happened

Alfred J. Novak, a director of Pasithea Therapeutics Corp. (KTTA), received a derivative award on May 1, 2026 covering 152,783 shares. The filing lists the transaction as an award/grant (code A) with a reported price of $0.00. The instrument is described in the filing as an "Option" under the Issuer's 2023 Stock Incentive Plan.

Key Details

Transaction date: 2026-05-01; Form 4 filed: 2026-05-05 (appears timely — within the standard two business-day reporting window).
Shares/units granted: 152,783 (derivative award; reported price $0.00).
Shares owned after transaction: not stated in the provided excerpt of the filing.
Footnote: the Option vests in full on the one-year anniversary of the grant if Novak remains a director; the shares will fully vest upon a Change in Control (per the 2023 Stock Incentive Plan).
Transaction code: A = Award/Grant (derivative), not an open-market purchase or sale.

Context

This was a grant of an option-like award, not an immediate stock purchase. Until the award vests and any option is exercised (if applicable), Novak does not have freely tradable common shares from this grant.
The filing does not report an intrinsic dollar value; the economic value depends on KTTA’s market price and any exercise terms. The vesting condition (one-year service or acceleration on change in control) is typical for director incentive grants.

Form 4

Period: 2026-05-01

Director

Transactions

Award
Stock Option (right to buy)
[F1]
2026-05-01+152,783→ 152,783 total
Exercise: $0.84Exp: 2036-04-30→ Common Stock (152,783 underlying)

Footnotes (1)

[F1]The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan).

Signature

/s/ Alfred J. Novak|2026-05-05

1 file